Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

MOUNTAIN VIEW, Calif., May 3, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE™ (loxapine) inhalation powder, 5 mg and 10 mg.  The CRL was issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  ADASUVE is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

In the CRL, the FDA noted, "During a recent inspection of the Mountain View, CA manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility.  Satisfactory resolution of these deficiencies is required before this application may be approved."  Alexza believes the deficiencies are medical device specific and readily addressable.  Alexza plans to meet with the FDA to gain a better understanding of the specific deficiencies and this meeting will be scheduled as soon as practical.  Alexza looks forward to working to resolve the remaining issues in a timely manner.

There were no new clinical or safety issues identified and there were no other deficiencies outlined in the CRL.  With respect to the ADASUVE Risk Evaluation and Mitigation Strategy (REMS), the CRL stated that discussions can continue on the proposed REMS after the response to the action letter has been submitted.  The CRL also contained comments on Alexza's draft product labeling.  Alexza believes that there is substantial agreement between Alexza and the FDA on the REMS and product labeling.

Conference Call Information - 8:00 a.m. Eastern Time on May 4, 2012
To a
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... In a recent study it ... of the Eldor spinal needle 25G, 103 mm appeared ... point spinal needles of the same gauge and length ... is an excellent type of regional anesthesia for many ... It is estimated that 100 million patients ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... 2011 Actavis Group, an international generic pharmaceuticals company, ... US Food & Drug Administration to market Valacyclovir Hydrochloride ... and 1 gram, the generic equivalent of Valtrex® by ... the 12 months ending December 31, 2010, according to ...
... 2011 NephRx Corporation today announced issuance of a ... factor peptide NX002 as a potential treatment for inflammatory ... have applications in acute and chronic diseases of the ... has been shown to stimulate the growth of epithelial ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
(Date:9/30/2014)... 2014 Keystone Symposia will convene the first conference ... 2014-15 Global Health Series on "The Modes of ... immediately following the conclusion of the Grand Challenges ... part of the Keystone Symposia Global Health Series, supported ... also funded travel awards for 36 investigators from developing ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
(Date:9/30/2014)... A University of Maryland-led research team has been ... National Institutes of Health (NIH) to develop new ... further our understanding of how large networks of ... information. This knowledge will help researchers identify the ... drive behavior, like decision-making and speaking, and alterations ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... (IADR) announces Dr. Anthony Fauci, director, National Institute of ... of Health in Bethesda, Md., USA as 2009 IADR ... the 87th General Session & Exhibition in Miami, Florida, ... Fauci became director of NIAID, where he oversees an ...
... Thirty-seven scientists from Cold Spring Harbor Laboratory (CSHL) and 20 ... issued a major challenge to the neuroscience community. At ... just-published paper, to assemble a comprehensive map of the major ... in which the genomes of many organisms, including that of ...
... a lot of a hormone needed to eliminate the excess ... the enzyme needed to activate it, researchers say. , ... found people in heart failure have less of the enzyme ... hormone made by heart muscle cells that, when active, helps ...
... Society Emphasizes A Special Calling: Knowledge ... Leadership ... A ... With a majority of its nurses nearing ... is urging its members to respond to a new calling ... National Wound, Ostomy and Continence Nurses Week, April 12 - ...
... March 31 Pacific Fertility Center is pleased to ... diagnosis (PGD) and preimplantation genetic screening (PGS). Recent ... The use of this science for such "futuristic" action ... it is used today. Pacific Fertility Center is proud ...
... The not-for-profit LENA Foundation is putting forth a ... Society of Research in Child Development (SRCD). At the ... one poster will be presented based on findings using ... SRCD is a great opportunity for our colleagues to ...
Cached Medicine News:Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 2Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 4Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 5Health News:New tests provide new insight into why patients are in heart failure 2Health News:New tests provide new insight into why patients are in heart failure 3Health News:Wound, Ostomy & Continence Nurses Society Focuses On Preparing the Next Generation of Leaders 2Health News:Wound, Ostomy & Continence Nurses Society Focuses On Preparing the Next Generation of Leaders 3Health News:PGD Technology Offers More Than Designer Babies 2Health News:PGD Technology Offers More Than Designer Babies 3Health News:PGD Technology Offers More Than Designer Babies 4Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: